Comparison of post-RFIB and post-operative clinical target volumes in breast-conserving therapy: A prospective cohort study
Completed
- Conditions
- breast cancermammary malignancy10006291
- Registration Number
- NL-OMON35489
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
- Female gender;
- Age >=18
- cTis-T1N0 breast cancer;
- RFIB procedure showing microscopically tumor free resection margins
- Scheduled for breast-conserving therapy (BCS + WBRT);
- Before breast-conserving surgery;
- Written informed consent.
Exclusion Criteria
- Legal incapability;
- Insufficient command of the Dutch language;
- Inability to maintain the standard supine RT treatment position for 30 minutes;
- Treated with neo-adjuvant systemic therapy;
- Treated with a modified radical mastectomy or breast amputation.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>CTV-RFIB and CTV-POC.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular markers influence post-RFIB clinical target volume accuracy in breast-conserving therapy for mammary malignancy?
How does post-RFIB target volume delineation compare to post-operative methods in predicting local recurrence rates in breast cancer patients?
Which biomarkers correlate with improved outcomes in NL-OMON35489 observational study of breast-conserving therapy target volumes?
What adverse events are associated with post-RFIB versus post-operative clinical target volume approaches in UMC Utrecht breast cancer trials?
How do RFIB-derived target volumes integrate with standard-of-care radiation protocols for ER/PR/HER2 subtypes in breast-conserving therapy?